Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 0 · 0%High 5 · 62.5%

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25449 participants
High

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25480 participants
High

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortalityÂ

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
2 studies · 27029 participants
High

Any adverse eventh

WIBP‐CorV – Sinopharm‐Wuhan leads to lower any adverse eventh compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.96 [0.93, 0.98]
2 studies · 27029 participants
High

Serious adverse eventsi

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.83 [0.6, 1.15]
2 studies · 27029 participants
Low

Local reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan leads to lower local reactogenicity eventsk compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.88 [0.85, 0.92]
2 studies · 27029 participants
High